Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Gardner, Erin R ^a   Smith, Nicola F ^b   Figg, William D ^b   Sparreboom, Alex ^b,c  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; TARIQUIDAR; ABC TRANSPORTER; ABCB1 PROTEIN, MOUSE; ABCG2 PROTEIN, MOUSE; ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG UPTAKE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; MALE; MICE; MICE, INBRED BALB C; P-GLYCOPROTEIN; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINOLINES;

EID: 68749104738     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-99     Document Type: Article

References (21)

1. Clinical pharmacokinetics of imatinib. B Peng P Lloyd H Schran, Clin Pharmacokinet 2005 44 879 894 10.2165/00003088-200544090-00001 16122278 (Pubitemid 41252840)
2. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. DA Reardon MJ Egorin JA Quinn JN Rich S Gururangan JJ Vredenburgh A Desjardins S Sathornsumetee JM Provenzale JE Herndon 2nd JM Dowell MA Badruddoja RE McLendon TF Lagattuta KP Kicielinski G Dresemann JH Sampson AH Friedman AJ Salvado HS Friedman, J Clin Oncol 2005 23 9359 9368 10.1200/JCO.2005.03.2185 16361636 (Pubitemid 46260195)
3. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. PY Wen WK Yung KR Lamborn PL Dahia Y Wang B Peng LE Abrey J Raizer TF Cloughesy K Fink M Gilbert S Chang L Junck D Schiff F Lieberman HA Fine M Mehta HI Robins LM DeAngelis MD Groves VK Puduvalli V Levin C Conrad EA Maher K Aldape M Hayes L Letvak MJ Egorin R Capdeville R Kaplan AJ Murgo C Stiles MD Prados, Clin Cancer Res 2006 12 4899 4907 10.1158/1078-0432.CCR-06-0773 16914578 (Pubitemid 44338577)
4. Interaction of imatinib mesilate with human P-glycoprotein. A Hamada H Miyano H Watanabe H Saito, J Pharmacol Exp Ther 2003 307 824 828 10.1124/jpet.103.055574 12975485 (Pubitemid 37310701)
5. Distribution of STI-571 to the brain is limited by P-glycoprotein- mediated efflux. H Dai P Marbach M Lemaire M Hayes WF Elmquist, J Pharmacol Exp Ther 2003 304 1085 1092 10.1124/jpet.102.045260 12604685 (Pubitemid 36254421)
6. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). KE Kil YS Ding KS Lin D Alexoff SW Kim C Shea Y Xu L Muench JS Fowler, Nucl Med Biol 2007 34 153 163 10.1016/j.nucmedbio.2006.11.004 17307123 (Pubitemid 46251643)
7. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. PJ Houghton GS Germain FC Harwood JD Schuetz CF Stewart E Buchdunger P Traxler, Cancer Res 2004 64 2333 2337 10.1158/0008-5472.CAN-03-3344 15059881 (Pubitemid 38523883)
8. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. H Burger H van Tol AW Boersma M Brok EA Wiemer G Stoter K Nooter, Blood 2004 104 2940 2942 10.1182/blood-2004-04-1398 15251980 (Pubitemid 39434984)
9. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. P Breedveld D Pluim G Cipriani P Wielinga O van Tellingen AH Schinkel JH Schellens, Cancer Res 2005 65 2577 2582 10.1158/0008-5472.CAN-04-2416 15805252 (Pubitemid 40490054)
10. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. M Maliepaard GL Scheffer IF Faneyte MA van Gastelen AC Pijnenborg AH Schinkel MJ van De Vijver RJ Scheper JH Schellens, Cancer Res 2001 61 3458 3464 11309308 (Pubitemid 32695041)
11. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. ER Lepper K Nooter J Verweij MR Acharya WD Figg A Sparreboom, Pharmacogenomics 2005 6 115 138 10.1517/14622416.6.2.115 15882131 (Pubitemid 40613179)
12. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. B Sarkadi L Homolya G Szakacs A Varadi, Physiol Rev 2006 86 1179 1236 10.1152/physrev.00037.2005 17015488 (Pubitemid 44521651)
13. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. H Burger H van Tol M Brok EA Wiemer EA de Bruijn G Guetens G de Boeck A Sparreboom J Verweij K Nooter, Cancer Biol Ther 2005 4 747 752 15970668 (Pubitemid 41351174)
14. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. S Bihorel G Camenisch M Lemaire JM Scherrmann, Pharm Res 2007 24 1720 1728 10.1007/s11095-007-9278-4 17380257 (Pubitemid 47206611)
15. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. P Mistry AJ Stewart W Dangerfield S Okiji C Liddle D Bootle JA Plumb D Templeton P Charlton, Cancer Res 2001 61 749 758 11212278 (Pubitemid 32128642)
16. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. E Fox SE Bates, Expert Rev Anticancer Ther 2007 7 447 459 10.1586/14737140.7.4.447 17428165 (Pubitemid 46681800)
17. Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection. ER Lepper JK Hicks J Verweij S Zhai WD Figg A Sparreboom, J Chromatogr B Analyt Technol Biomed Life Sci 2004 806 305 310 10.1016/j.jchromb.2004.04.003 15171944 (Pubitemid 38686522)
18. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. K Beppu J Jaboine MS Merchant CL Mackall CJ Thiele, J Natl Cancer Inst 2004 96 46 55 14709738 (Pubitemid 38180959)
19. Modulation of the Brain Distribution of Imatinib and its Metabolites in Mice by Valspodar, Zosuquidar and Elacridar. S Bihorel G Camenisch M Lemaire JM Scherrmann, Pharm Res 2007 24 9 1720 8 10.1007/s11095-007-9278-4 17380257 (Pubitemid 47206611)
20. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. EF Choo D Kurnik M Muszkat T Ohkubo SD Shay JN Higginbotham H Glaeser RB Kim AJ Wood GR Wilkinson, J Pharmacol Exp Ther 2006 317 1012 1018 10.1124/jpet.105.099648 16537797 (Pubitemid 43764103)
21. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. AH Dantzig DP de Alwis M Burgess, Adv Drug Deliv Rev 2003 55 133 150 10.1016/S0169-409X(02)00175-8 12535578 (Pubitemid 36078455)